SWISF - New to The Street TV Announces Episode #552 with its Five Business Guest Interviews Airs on Bloomberg TV as Sponsored Programming Tonight February 1 2024 at 9:30 PM PT | Benzinga
NEW YORK, Feb. 01, 2024 (GLOBE NEWSWIRE) -- FMW Media's New to The Street TV announces the broadcasting of its business show airing on Bloomberg TV as sponsored programming tonight, Thursday, February 1, 2024, at 9:30 PM PT.
New to The Street's TV episode #552 will air the following five (5) business interviews:
1). Biopharmaceutical - Acurx Pharmaceuticals, Inc.'s (NASDAQ:ACXP) () interview with David Luci, President/CEO.
2). Decentralized Supercomputing – Dynex's (CRYPTO: DNX) () interview with Clifford Mapp, an Independent Technology Expert and Blockchain Pioneer.
3). Coffee - NuZee, Inc.'s (NUZE) () interview with Masateru Higashida, Founder, Chairman, and CEO.
4). Sports Academy - IMG Academy's interview with Tim Pernetti, President.
5). "Sekur Privacy & Sekur Security – Weekly Hack" segment with internet privacy expert Mr. Alain Ghiai, CEO, Sekur Private Data, Ltd. (OTCQB:SWISF) (CSE:SKUR) (FRA: GDT0) () (Sekur®).
Episode 552
New to The Street's TV Host Jane King from the Nasdaq MarketSite Studio talks with David Luci, the President/CEO of Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) (). As a clinical-stage biopharmaceutical business, ACXP is developing a new class of antibiotics for life-threatening bacterial infections. David updates viewers on the Company's FDA Phase 2 clinical trial on the Ibezapolstat drug, a treatment for patients with Clostridioides difficile Infections (CDI). Based on positive data from Phase 2a and Phase 2b, management is now going forward with the FDA Phase 3. The Company compared its top-line data with the currently used standard-of-care drugs in the marketplace, and Ibezapolstat has impressive positive results. Phases 2a and 2b confirmed that the drug had approximately 94% success with no reinfections. In treated patients, the microbiome bacteria found in the digestive tract shows the bacteria maintaining and restoring itself within those patients after a 10-day treatment. At a recent microbiome conference presentation in Texas, the Company compared logarithmic results from a competitor drug (vancomycin) to its Ibezapolstat drug, showing the differences in the effects on gut microbiome bacteria. Competitor drugs have been used for decades to treat CDI, but the reinfection rates are very high and greatly diminished gut microbiome bacteria. ACXP's Ibezapolstat study results have shown to combat reinfections effectively. Based on the data and other publications regarding the market size for newly discovered and effective treatment of CDI, ACXP believes Ibezapolstat could be a market worth over $1B. Decades-old antibacterial drugs are not working due to changes in the molecular composition of CDI. Thousands of people worldwide die annually, with many catching CDI in hospitals and nursing homes. Acurx Pharmaceuticals, Inc. believes its Ibezapolstat drug is the next generation for effectively treating CDI. Throughout 2024, Investors and others should expect more exciting news about Ibezapolstat and other positive corporate ongoings. The on-screen QR code is available during the show; download or visit Acurx Pharmaceuticals, Inc. - https://www.acurxpharma.com/.
From the Nasdaq MarketSite Studio, Clifford Mapp, an independent technology expert and blockchain pioneer, talks about Dynex (CRYPTO: DNX) () with New to The Street's TV Host Jane King. Clifford explains Dynex's technology platform that can provide supercomputing services to everyone and every industry at a fraction of the cost. Dynex offers a decentralized supercomputer platform, disrupting the supercomputing hardware and software legacy industries. Using a neuromorphic blockchain-based algorithm on its DynexSolve Chip, Dynex creates quantum-level computation services that can solve complex problems. Clifford says that neuromorphic networks use logical gateways to process information, mimicking the human brain in collecting and understanding information. Dynex Marketplace is a decentralized platform where anyone can access the system; end-users pay Dynex according to the time needed to process a computational outcome. Generally, Clifford states that it costs about $8 for a 3–5-minute runtime on their system, is very affordable, and results provide valuable data. An automotive company uses Dynex for a virtual reality wind tunnel. Instead of paying millions of dollars for construction, maintenance, and administrative costs for a wind tunnel, the automotive engineers engage Dynex supercomputer services to create cost-effective and timely produced datasets on automotive designs. The medical and pharmaceutical industries can benefit from Dynex, giving information on cancer, genetics, blood, and drug use outcomes. A pharmaceutical company could use the Dynex in a matter of minutes to see data on how the human body maintains itself after a 10-year drug use. The financial industry is another example of an industry that can make immediate computations on stock market forecasting and other financial stats. The Company has an entire staff of professionals to manage and support any clients who need to formulate a problem-solving solution on the system. Dynex Neuromorphic Computing platform is decentralized, allowing for complex computations without expensive infrastructures and providing cost-effective outcomes. The on-screen QR code is available during the show; download or visit Dynex - https://dynexcoin.org/.
New to The Street's TV Host Jane King is at the Nasdaq MarketSite Studio with Masateru Higashida, Founder, Chairman, and CEO of NuZee, ...